Three-Month Dual Antiplatelet Therapy After Implantation of Zotarolimus-Eluting Stents - The DATE (Duration of Dual Antiplatelet Therapy After Implantation of Endeavor Stent) Registry -

Authors
Joo-Yong HahnYoung Bin SongJin-Ho ChoiSung-Hyuk ChoiSung Yun LeeHun Sik ParkSeung Ho HurSahng LeeKyoo-Rok HanSeung-Woon RhaByung Ryul ChoJong-Sun ParkJunghan YoonDo Sun LimSang Hoon LeeHyeon-Cheol Gwon
Department
Dept. of Internal Medicine (내과학)
Issue Date
2010
Citation
Circulation Journal, Vol.74(11) : 2314-2321, 2010
ISSN
1346-9843
Abstract
Background: The optimal duration of dual antiplatelet therapy remains controversial. Methods and Results: Between December 2006 and March 2008, 823 patients were enrolled in a prospective multicenter registry for 3-month dual antiplatelet therapy (aspirin 100–200 mg+clopidogrel 75 mg daily) followed by aspirin mono-therapy after zotarolimus-eluting stents (ZES). Major exclusion criteria were: cardiogenic shock, stent thrombosis (ST)-segment elevation myocardial infarction (MI) within 48 h, previous drug-eluting stent implantation, severe left ventricular dysfunction, bifurcation lesions requiring 2-stenting, left main and graft lesions. The primary outcome was a composite of cardiac death, MI, or ST at 1 year. The median duration of dual antiplatelet therapy was 95 days (interquartile range 90–101). At 1 year, 3 patients (0.4%) had cardiac deaths, 3 patients (0.4%) had MI, and 4 patients (0.5%) had definite or probable ST, leading to the primary outcome in 5 patients (0.6%). Death, MI, or any revascularization occurred in 68 patients (8.3%). Among patients who were event-free at 3 months (n=812), clopidogrel was discontinued at 3 months in 661 patients and was continued for longer than 3 months in 151 patients. Discontinuation of clopidogrel at 3 months did not increase the primary outcome (HR 0.90; 95%CI, 0.09–9.02), death, MI, or any revascularization (HR 0.89; 95%CI, 0.48–1.67) after adjustment for the propensity score. Conclusions: Three-month dual antiplatelet therapy seems to be feasible after ZES implantation in relatively low-risk patients. (Circ J 2010; 74: 2314 – 2321) Key Words: Antiplatelets; Drug-eluting stents
URI
http://kumel.medlib.dsmc.or.kr/handle/2015.oak/35433
Appears in Collections:
1. Journal Papers (연구논문) > 1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
Keimyung Author(s)
허승호
File in this Item
oak-aaa-01393.pdf(673.06 kB)Download
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE